Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357

Interpreting the significance of changes in health-related quality-of-life scores.

Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Wang, L., Yang, Z., Guo, F., Chen, Y., Wei, J., Dai, X., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1227797 · Cited by 22

Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?

Riondino, S., Rosenfeld, R., Formica, V., Morelli, C., Parisi, G., Torino, F., Mariotti, S., & Roselli, M. (2024) · Cancers · doi:10.3390/cancers16071251 · Cited by 20

Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer

Bragadin, A. B., Bianco, P. D., Zulato, E., Attili, I., Pavan, A., Carlet, J., Marra, L., Guarneri, V., Indraccolo, S., & Bonanno, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00704-9 · Cited by 20

Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer

Dai, J., Zhu, X., Li, D., Huang, Y. J., Liu, X., He, W., Duan, L., Zhao, D., Zhu, Y., Chen, C., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-56 · Cited by 20

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial

Moreno, V., Roda, D., Pikiel, J., Trigo, J. M., Bosch‐Barrera, J., Drew, Y., Kristeleit, R. S., Hiret, S., Bajor, D. L., Cruz, P., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.05.013 · Cited by 20

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

Mizuno, T., Katsuya, Y., Sato, J., Koyama, T., Shimizu, T., & Yamamoto, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925938 · Cited by 21

Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario

Bertaglia, V., Morelli, A. M., Solinas, C., Aiello, M. M., Manunta, S., Denaro, N., Tampellini, M., Scartozzi, M., & Novello, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103954 · Cited by 20

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

Huang, Y., Zhao, J. J., Soon, Y. Y., Kee, A. C.-L., Tay, S. H., Aminkeng, F., Ang, Y. L. E., Wong, A. S. C., Bharwani, L. D., Goh, B. C., et al. (2023) · Cancers · doi:10.3390/cancers15102733 · Cited by 20

Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis

Suay, G., García‐Cañaveras, J. C., Aparisi, F., Lahoz, A., & Juan, Ó. (2023) · Cancers · doi:10.3390/cancers15184433 · Cited by 22

Immunotherapy in patients with brain metastasis: advances and challenges for the treatment and the application of circulating biomarkers

Brozos-Vázquez, E., Rodríguez-López, C., Cortegoso-Mosquera, A., López-Landrove, S., Muinelo‐Romay, L., García, J., López‐López, R., & León‐Mateos, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1221113 · Cited by 20

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer

Jiang, C. Y., Zhao, L., Green, M. D., Ravishankar, S., Towlerton, A. M. H., Scott, A. J., Raghavan, M., Cusick, M. F., Warren, E. H., & Ramnath, N. (2024) · Scientific Reports · doi:10.1038/s41598-023-48546-y · Cited by 20

Advancing non-small cell lung cancer treatment: the power of combination immunotherapies

Wu, Y., Yu, G., Jin, K., & Qian, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1349502 · Cited by 23

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

Krzyżanowska, N., Wojas‐Krawczyk, K., Milanowski, J., & Krawczyk, P. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063087 · Cited by 19

Immunotherapy combined with chemotherapy versus chemotherapy alone as the first‐line treatment of PD‐L1 ‐negative and driver‐gene‐negative advanced nonsquamous non‐small‐cell lung cancer: An updated systematic review and meta‐analysis

Chai, Y., Wu, X., Zou, Y., Zhang, X., Bai, H., Dong, M., & Duan, J. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14664 · Cited by 20

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Gümüş, M., Chen, C.-I., Ivanescu, C., Kılıçkap, S., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Türk, H. M., Çiçin, İ., Harnett, J., et al. (2022) · Cancer · doi:10.1002/cncr.34477 · Cited by 19

Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis

Zhang, X., Ge, N., Xiang, Z.-J., & Liu, T. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02760-2 · Cited by 20

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer

Pelicon, V., Čufer, T., & Knez, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1182748 · Cited by 20

Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis

Zhu, L., Wu, J., Gao, H., Wang, T. I., Xiao, G., Hu, C., Lin, Q., & Zhou, Q. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002525 · Cited by 19

Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review

Guo, H., Zhang, J., Qin, C., Yan, H., Luo, X., & Zhou, H. (2024) · Medicine · doi:10.1097/md.0000000000036861 · Cited by 19

Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer

Li, T., Ma, W., & Al-Obeidi, E. (2024) · Cancers · doi:10.3390/cancers16132350 · Cited by 19

Qingfei Jiedu decoction inhibits PD-L1 expression in lung adenocarcinoma based on network pharmacology analysis, molecular docking and experimental verification

Pan, J., Yang, H., Zhu, L., Lou, Y., & Jin, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.897966 · Cited by 19

Personalized treatment for patients with lung cancer

Schüler, M., Bölükbas, S., Darwiche, K., Theegarten, D., Herrmann, K., & Stuschke, M. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0012 · Cited by 20

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail

Daylan, A. E. C., & Halmos, B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-245 · Cited by 18

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Wang, F., Xia, T., Li, Z., Gao, X., & Fang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1213297 · Cited by 19

Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices

Roque, K., Ruiz, R., Mas, L. A., Pozza, D. H., Vancini, M., Silva, J. A., & de Mello, R. A. (2023) · Cancers · doi:10.3390/cancers15184547 · Cited by 19

Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?

Spagnolo, C. C., Pepe, F., Ciappina, G., Nucera, F., Ruggeri, P., Squeri, A., Speranza, D., Silvestris, N., Malapelle, U., & Santarpía, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104332 · Cited by 18

The role of immunotherapy in early-stage and metastatic NSCLC

Lieber, A., Makai, A., Orosz, Z. Z., Kardos, T., Isaac, S. J., Tornyi, I., & Bittner, N. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611713 · Cited by 18

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors

Schlauch, D., Fu, X., Jones, S. F., Burris, H. A., Spigel, D. R., Reeves, J. A., & McKenzie, A. J. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00008 · Cited by 18

Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis

Li, F., Zhai, S., Lv, Z., Yuan, L., Wang, S., Jin, D., Yi, H., Fu, L., & Mao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968517 · Cited by 17

Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer

Khadela, A. D., Chavda, V. P., Postwala, H. I., Ephraim, R., Apostolopoulos, V., & Shah, Y. B. (2023) · Cancers · doi:10.3390/cancers15020543 · Cited by 18

Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non–small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90%

Shah, M., Mamtani, R., Marmarelis, M. E., & Hennessy, S. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.02.007 · Cited by 17

FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer

Grell, P., Bořilová, S., Fabián, P., Selingerová, I., Novak, D., Müller, P., Kišš, I., & Vyzula, R. (2023) · Cancers · doi:10.3390/cancers15061901 · Cited by 18

Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study

Liu, Y.-G., Jiang, S., Zhang, L., Zheng, H., Zhang, T., Zhang, J., Zhao, H., Sang, X., Xu, Y., & Lu, X. (2023) · European journal of medical research · doi:10.1186/s40001-023-01195-3 · Cited by 17

First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis

He, M., Zheng, T., Zhang, X., Peng, Y., Jiang, X., Huang, Y., Tan, B., & Yang, Z. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03089-x · Cited by 17

Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis

Hao, W., Zhang, J., Wang, Y., Fang, B., Jin, S., Yuan, J., & Cai, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175809 · Cited by 17

The aryl hydrocarbon receptor controls IFN-γ-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma

Snyder, M., Wang, Z., Lara, B., Fimbres, J., Pichardo, T., Mazzilli, S. A., Khan, M. M., Duggineni, V. K., Monti, S., & Sherr, D. H. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkae023 · Cited by 17

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer

Lü, S., Fang, J., Wang, Z., Fan, Y., Liu, Y., He, J., Zhou, J., Hu, J., Xia, J., Liu, W., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5144 · Cited by 16

Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?

Meshulami, N., Tavolacci, S. C., de Miguel‐Pérez, D., Rolfo, C. D., Mack, P. C., & Hirsch, F. R. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.03.014 · Cited by 16

Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma

GIORGI, V. D., Trane, L., Savarese, I., Silvestri, F., Venturi, F., Zuccaro, B., & Scarfì, F. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14804 · Cited by 16

PD-1/PD-L1 inhibitors in treatment-naïve, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials

Wankhede, D., Hofman, P. M., & Grover, S. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04286-6 · Cited by 15

Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials

Liu, H., Luo, S. X., Jie, J., Peng, L., Wang, S., & Song, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1115305 · Cited by 15

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study

Elkrief, A., Alessi, J. V., Ricciuti, B., Brown, S., Rizvi, H. A., Preeshagul, I. R., Wang, X., Pecci, F., Federico, A. D., Lamberti, G., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006994 · Cited by 15

Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes

Blanco, R., Dómine, M., González, J. L., Loutfi, S., Alfaro, J., Saldaña, J., Rubio, J., Campos, B., Hidalgo, J., Joaquín, A. B., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107318 · Cited by 15

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC

Marchi, P. D., Leal, L. F., da Silva, L. S., Cavagna, R. D. O., da Silva, F. A. F., da Silva, V. D., da Silva, E. C. A., Saito, A. O., de Lima, V. C. C., & Reis, R. M. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101818 · Cited by 15

Immunotherapy in the First-Line Setting in Wild-Type NSCLC

Denault, M.-H., & Melosky, B. L. (2021) · Current Oncology · doi:10.3390/curroncol28060378 · Cited by 15

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases

Yang, G., Xing, L., & Sun, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852811 · Cited by 15

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%

Attili, I., Valenza, C., Santoro, C., Antonarelli, G., Aliaga, P. T., Signore, E. D., Catania, C., Spitaleri, G., Passaro, A., & de Marinis, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.980765 · Cited by 15

Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer

Fu, F., Deng, C., Sun, W., Zheng, Q., Jin, Y., Li, Y., Zhang, Y., & Chen, H. (2022) · Respiratory Research · doi:10.1186/s12931-022-02201-8 · Cited by 17

Biomarkers in the management of lung cancer: changing the practice of thoracic oncology

Melichar, B. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1108 · Cited by 15

Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma

Xu, H., Wang, W., Yin, J., Song, C., Li, L., & Sun, Z. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s388777 · Cited by 15

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Gambale, E., Fancelli, S., Caliman, E., Petrella, M. C., Doni, L., Pillozzi, S., & Antonuzzo, L. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003540 · Cited by 15

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0

Reuss, J. E., Bazhenova, L. A., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02825 · Cited by 14

Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis

Yang, B., Wang, B., Chen, Y., Wan, N., Xie, F., Yang, N., Lu, L., Xiao, W., Yuan, J., Li, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1044327 · Cited by 14

Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis

Zhang, C., Wei, F., Ma, W., & Zhang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1255825 · Cited by 15

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed

Leonetti, A., Perrone, F., Puntoni, M., Maglietta, G., Bordi, P., Bria, E., Vita, E., Gelsomino, F., Giglio, A. D., Gelibter, A. J., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114006 · Cited by 14

Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants

Gao, F., You, X., Yang, L., Zou, X., & Sui, B. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2333275 · Cited by 14

Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system

Liang, X., Xiao, H., Li, H., Chen, X., & Li, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1396752 · Cited by 14

Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis

Zhang, X., Wu, M., Chen, J., Zheng, K., Du, H., Li, B., Gu, Y., & Jiang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30809 · Cited by 14

The rapidly changing field of predictive biomarkers of non-small cell lung cancer

Tóth, L. J., Mokánszki, A., & Méhes, G. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611733 · Cited by 15

Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer

Reyes, A., Muddasani, R., & Massarelli, E. (2024) · Cancers · doi:10.3390/cancers16162919 · Cited by 14

Thoracic neoplasms

Krzakowski, M. J., Jassem, J., Antczak, A. J., Błasińska, K., Chorostowska‐Wynimko, J., Dziadziuszko, R., Głogowski, M., Grodzki, T., Kowalski, D. R., Krenke, R., et al. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2021.0022 · Cited by 16

Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Lage, Y., Olmedo, M. E., Rueda, A. G., Ballesteros, P. Á., Rodríguez, D. R., & Velasco, M. T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113245 · Cited by 15

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

Moreno, V., Garrido, P., Papadopoulos, K. P., Miguel, M. J. D., Gil-Martín, M., Aljumaily, R. M., Rosen, L. S., Rietschel, P., Mohan, K. K., Yoo, S., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.034 · Cited by 14

Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies

Yang, X., Luo, B., Tian, J., Wang, Y., Lu, X., Ni, J., Yang, Y., Jiang, L., & Ren, S. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00287-0 · Cited by 13

The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors

Stone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 13

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors

Hu, X., Wang, L., Shang, B., Wang, J., Sun, J., Liang, B., Su, L., You, W., & Jiang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094414 · Cited by 13

Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer

Divan, H. A., Bittoni, M. A., Krishna, A., & Carbone, D. P. (2024) · BMC Cancer · doi:10.1186/s12885-024-12126-8 · Cited by 13

Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab

Ricciuti, B., Elkrief, A., Lin, J., Zhang, J. J., Alessi, J. V., Lamberti, G., Gandhi, M. M., Federico, A. D., Pecci, F., Wang, X., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100675 · Cited by 13

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial

Baramidze, A., Makharadze, T., Gogishvili, M., Melkadze, T., Giorgadze, D., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107821 · Cited by 13

Dual-signal output biosensor for the detection of program death-ligand 1 and therapy progress monitoring of cancer

Saputra, H. A., Chung, J. H., Sahin, M. A. Z., Park, D., & Shim, Y. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116565 · Cited by 13

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

Zhang, H., Zhang, Y., Zhu, Y., Dong, T., & Liu, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387345 · Cited by 14

Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer

Chen, Q., Ying, S., Qin, J., & Zhang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1384906 · Cited by 14

Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study

Lü, S., Wu, L., Wang, Q., Wang, Z., Lv, D., Ma, R., Zhu, B., Tran, N. V., Jiang, L., Nan, K., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.10.024 · Cited by 14

Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions

Ghazali, N., Garassino, M. C., Leighl, N. B., & Bestvina, C. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251323985 · Cited by 13

Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients

Xue, C., Zheng, S., Dong, H., Lu, X., Zhang, X., Zhang, J., Li, J., & Cui, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627016 · Cited by 14

New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer

Corke, L., & Sacher, A. G. (2021) · Current Oncology · doi:10.3390/curroncol29010004 · Cited by 15

Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis

Kim, J., Ha, H., Park, J., Cho, J., Lim, J. H., & Lee, M. H. (2021) · Journal of Cancer · doi:10.7150/jca.65374 · Cited by 13

A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non–Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

Osta, B. E. E., Carlisle, J. W., Steuer, C. E., Pakkala, S., Leal, T. A. B., Dhodapkar, M. V., Liu, Y., Chen, Z., Owonikoko, T. K., & Ramalingam, S. S. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.003 · Cited by 13

Programmed death ligand 1 and tumor-infiltrating CD8+ T lymphocytes are associated with the clinical features in meningioma

Zhang, Y., Wang, X., Shi, M., Song, Y., Yu, J., & Han, S. (2022) · BMC Cancer · doi:10.1186/s12885-022-10249-4 · Cited by 13

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

Pang, L., Gan, J., Huang, Y., Liao, J., Zhuang, W., Ali, W. A. S., Hong, S., Zhang, L., & Fang, W. (2023) · BMC Cancer · doi:10.1186/s12885-022-10446-1 · Cited by 13

Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials

Xu, Z., Liang, J., Fu, R., Yang, L., Chen, Y., Ren, W., Lü, Y., Qiu, X.-X., & Gu, Q. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.07.012 · Cited by 15

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer

Liu, X., & Chi, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1211815 · Cited by 15

Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases

Mahashabde, R. V., Bhatti, S. A., Martin, B. C., Painter, J. T., Rodriguez, A., Ying, J., & Li, C. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00042 · Cited by 13

BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non–small cell lung cancer

Liu, J., Li, J., Tuo, Z., Hu, W., & Liu, J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105302 · Cited by 13

Insights into the Mechanisms of Immune‐Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment

Zhang, Y., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202508692 · Cited by 13

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations

Ahn, J., & Nagasaka, M. (2023) · Cancer Management and Research · doi:10.2147/cmar.s325856 · Cited by 12

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

Isla, D., Sánchez-Hernández, A., Casal, J., Cobo, M., Majem, M., Reguart, N., Zugazagoitia, J., & Bernabé, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155063 · Cited by 12

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%

Chen, W., Chen, J., Zhang, L., Cheng, S., & Yu, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11285-4 · Cited by 12

Immune-Related Adverse Events in Patients with Lung Cancer

Correia, G. S. D. C., Pai, T., Li, S., Connor, D., Zhao, Y., Lou, Y., & Manochakian, R. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01462-w · Cited by 12

The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials

Kong, Y., Hong, L., Xu, X., Chen, Y.-F., & Xu, J. H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301931 · Cited by 12

β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer

Geng, Q., Lu, Y., Li, D., Qin, L., Qi, C., Pu, X., Zhuang, Y., Zhu, Y. E., Zha, Q., Wang, G., et al. (2024) · BMC Immunology · doi:10.1186/s12865-024-00651-x · Cited by 12

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Acker, F., Reck, M., Martin, D., Rieken, S., Heinzen, S., Rost, M., Aguinarte, L., Schulte, H., Serve, H. L., Oellerich, T., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115266 · Cited by 13

Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

Chen, H., Feng, Y., Zhou, Y. L., Tao, Y., Tang, L. M., & Shi, Y. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03224-2 · Cited by 12

Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer

Shah, M., Marmarelis, M. E., Mamtani, R., & Hennessy, S. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.003 · Cited by 12

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer

Spagnuolo, A., & Gridelli, C. (2023) · Cancers · doi:10.3390/cancers15082319 · Cited by 13

Abnormal low expression of SFTPC promotes the proliferation of lung adenocarcinoma by enhancing PI3K/AKT/mTOR signaling transduction

Zuo, B., Wang, L., Li, X., Li, X., Wang, J., Xiong, Y., Lei, J., Zhang, X., Chen, Y., Liu, Q., et al. (2023) · Aging · doi:10.18632/aging.205191 · Cited by 12

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

Giacomo, A. M. D., Schenker, M., Médioni, J., Mańdziuk, S., Majem, M., Gravis, G., Cornfeld, M. J., Ranganathan, S., Lou, S., & Csőszi, T. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102387 · Cited by 12

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

Cheng, M., Shao, Y., Li, L., Jiang, M., & Song, Z. (2024) · BMC Cancer · doi:10.1186/s12885-024-12043-w · Cited by 12

First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data

Boussageon, M., Swalduz, A., CHOUAID, C., & Bylicki, O. (2022) · BioDrugs · doi:10.1007/s40259-022-00515-z · Cited by 12

Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine

Lê, H., Seitlinger, J., Lindner, V., Olland, A., Falcoz, P., Benkirane-Jessel, N., & Quéméneur, É. (2022) · Biomedicines · doi:10.3390/biomedicines10071677 · Cited by 14

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Özgüroğlu, M., Kılıçkap, S., Sezer, A., Gümüş, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., Ho, G. F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00329-7 · Cited by 118

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Gogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M. V., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01977-y · Cited by 319

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Kılıçkap, S., Baramidze, A., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.03.033 · Cited by 39

119TiP An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice within Europe (CEMI-LUNG)

Gessner, C., Griesinger, F., Shah, R., Talbot, T., Venkateshan, S., Shankar, A. K. V., Seluzhytsky, A., & Marsden, D. M. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100223 · Cited by 3

P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Gümüs, M., Kılıçkap, S., Sezer, A., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., He, X., Gullo, G., Rietschel, P., & Quek, R. G. W. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.556